Design and optimization of selective and potent LSD1 inhibitors with tranylcypromine-pyrimidine scaffold for the treatment of acute myeloid leukemia

Key Points

• Inhibitors targeting LSD1 effectively reduced cancer cell proliferation in acute myeloid leukemia.
• Key metrics include a potency improvement of over 50% when tested in vitro against leukemia cell lines.
• Design and optimization focus on the tranylcypromine-pyrimidine scaffold for enhanced inhibition of LSD1.
• Highlights the need for further research into targeted therapies for acute myeloid leukemia; validation required.